← Back to search
UNIVERSITY OF OKLAHOMA
Doing business as BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
OKLAHOMA CITY, OK, 73104
UnclaimedClaim this profile (free)
Prime contracting experience
39 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Veterans Affairs Department of Veterans Affairs | RADIOPHARMACEUTICALS FOR MUS | — | $444,488 | Oct 1, 2026 | Oct 1, 2025 – Dec 31, 2026 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | PET/CT RADIOPHARMACEUTICALS | — | $377,946 | Oct 1, 2026 | Oct 1, 2023 – Sep 30, 2027 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | INTERVENTIONAL RADIOLOGY SERVICES | — | $1,388,044 | Oct 1, 2026 | Oct 1, 2021 – Mar 31, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | TRIPLE NEGATIVE BREAST CANCER VACCINES | 75N91024D00005USAspending | $1,147,754 | Sep 10, 2026 | Sep 14, 2026 – Sep 13, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: COLORECTAL CANCER (CRC) PREVENTION BY TPST-1495 IN PIRC RAT MODEL | 75N91019D00020USAspending | $1,140,397 | Jul 8, 2026 | Sep 11, 2023 – Sep 10, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | TASK ORDER TITLE: PREVENTING LUNG ADENOCARCINOMA (LUAD) USING TRAIL INDUCING AGENT, ONC201 BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS | 75N91019D00020USAspending | $982,258 | Jul 6, 2026 | Sep 8, 2022 – Aug 7, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | TO TITLE: A NOVEL MRNA VACCINE TO PREVENT TRIPLE NEGATIVE BREAST CANCER IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS | 75N91024D00005USAspending | $760,552 | Jun 22, 2026 | Jun 17, 2024 – Jun 16, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | PROJECT TITLE: FURTHER EVALUATION OF AMHR2-ED ANTIGENS FOR EPITHELIAL OVARIAN CARCINOMA | 75N91019D00020USAspending | $1,020,800 | Jun 17, 2026 | Sep 15, 2021 – Sep 14, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | BASE IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: FURTHER DEVELOPMENT OF MITOCHONDRIA-TARGETED HONOKIOL FOR PREVENTION OF LUNG CANCER: ADENOCARCINOMA A | 75N91024D00005USAspending | $1,234,179 | Jun 5, 2026 | Sep 25, 2025 – Mar 24, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | STRONG HEART STUDY (SHS)- COORDINATING CENTER (CC)- TASK ORDER 001 | 75N92019D00027USAspending | $14,413,239 | Jun 5, 2026 | Feb 15, 2019 – Feb 14, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | STRONG HEART STUDY (SHS)- FIELD CENTER (FC)- TASK ORDER 001 | 75N92019D00028USAspending | $5,273,991 | Jun 5, 2026 | Feb 15, 2019 – Feb 14, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM - A NOVEL MULTI-ANTIGEN VACCINE (TNBCVAX) TO PREVENT TRIPLE NEGATIVE BREAST CANCER | 75N91019D00020USAspending | $1,107,542 | Apr 10, 2026 | Sep 16, 2021 – Nov 15, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | EVALUATION OF TWO DIFFERENT CLASSES OF COMPOUNDS (STAT3 INHIBITORS AND SERMS) FOR THE PREVENTION OF URINARY BLADDER CANCER. | 75N91019D00020USAspending | $909,994 | Mar 18, 2026 | Sep 21, 2020 – Nov 1, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | STRONG HEART STUDY (SHS)- UNIVERSITY OF OKLAHOMA-FIELD CENTER (FC), TASK AREA B.3, YEAR 3 | 75N92019D00028USAspending | $333,373 | Feb 24, 2026 | Feb 15, 2024 – Oct 31, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | STRONG HEART STUDY (SHS) - UNIVERSITY OF OKLAHOMA, FIELD CENTER (FC), TASK AREA C: DATA BOOK | 75N92019D00028USAspending | $469,049 | Feb 4, 2026 | Jan 12, 2026 – Feb 14, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE | 75N91019D00020USAspending | $1,435,788 | Jan 13, 2026 | Aug 5, 2022 – Feb 4, 2027 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | RADIOPHARMACEUTICALS | 36C25923D0003USAspending | $429,877 | Dec 16, 2025 | Oct 1, 2024 – Sep 30, 2025 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | RADIOPHARMACEUTICALS | 36C25923D0003USAspending | $435,690 | Oct 1, 2025 | Oct 1, 2025 – Sep 30, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | CHEMOPREVENTION WITH MITOCHONDRIA-TARGETED HONOKIOL IN MOUSE MODELS OF LUNG CANCER: ADENOCARCINOMA AND SQUAMOUS CELL CARCINOMA | 75N91019D00020USAspending | $1,201,554 | Aug 11, 2025 | Sep 15, 2022 – Mar 14, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | STRONG HEART STUDY (SHS)- OKLAHOMA UNIVERSITY HEALTH CENTER (OUHSC) COORDINATING CENTER(CC) SUBTASK B.2 - PHASE VII EXAM AND EXAM CLOSEOUT. | 75N92019D00027USAspending | $1,218,378 | Jul 21, 2025 | Nov 1, 2022 – Aug 31, 2024 |
| Prime | Department of Health and Human Services National Institutes of Health | PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND ENDPOINT BIOMARKERS. TASK ORDER TITLE: URINARY BLADDER CANCER PREVENTION WITH TWO CLINICALLY-READY AGENTS (EVEROLIMUS AND NAPROXEN)WHEN ADMINISTERED IN COMBINATION. | 75N91019D00020USAspending | $780,910 | May 5, 2025 | Sep 21, 2020 – Jun 20, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | TASK ORDER TITLE: PREVENTING COLORECTAL CANCER USING TRAIL-INDUCING ONC201 ALONE OR IN COMBINATION WITH NSAID | 75N91019D00020USAspending | $878,817 | May 1, 2025 | Sep 15, 2020 – Mar 14, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | STRONG HEART STUDY (SHS)- COORDINATING CENTER (CC)- TASK AREA B.2. | 75N92019D00027USAspending | $1,332,779 | Feb 12, 2025 | Nov 1, 2023 – Jun 30, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | SHS OUHSC FC SUBTASK AREA B.2 PHASE VII EXAM AND EXAM CLOSEOUT. | 75N92019D00028USAspending | $678,572 | Dec 20, 2024 | Nov 1, 2022 – Mar 31, 2025 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | RADIOPHARMACEUTICALS | 36C25923D0003USAspending | $476,774 | Dec 5, 2024 | Oct 1, 2023 – Dec 6, 2024 |
| Prime | Department of Health and Human Services National Institutes of Health | STRONG HEART STUDY (SHS): OUHSC COORDINATING CENTER - TASK AREA B (B.1 AND B.3) | 75N92019D00027USAspending | $729,438 | Nov 25, 2024 | Apr 30, 2021 – Oct 31, 2022 |
| Prime | Department of Health and Human Services National Institutes of Health | STRONG HEART STUDY (SHS): OUHSC FIELD CENTER - TASK AREA B.1 AND B.3 | 75N92019D00028USAspending | $370,673 | Oct 24, 2024 | Apr 30, 2021 – Oct 31, 2022 |
| Prime | Department of Health and Human Services National Institutes of Health | BASE TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND ENDPOINT BIOMARKERS; TASK ORDER TITLE: EFGR AND KRAS VACCINE TO PREVENT LUNG CANCER | 75N91019D00020USAspending | $884,341 | Feb 5, 2024 | Jun 1, 2020 – Aug 31, 2023 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | RADIOPHARMACEUTICALS | 36C25923D0003USAspending | $368,583 | Nov 9, 2023 | Oct 1, 2022 – Sep 30, 2023 |
| Prime | Department of Health and Human Services National Institutes of Health | PREVENT EFFICACY POOL: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM | 75N91019D00020USAspending | $911,531 | Sep 8, 2023 | May 24, 2021 – Aug 23, 2024 |
| Prime | Department of Health and Human Services Office of the Assistant Secretary for Administration | PROJECT MAKING MEDICINE CULTURALLY ADAPTED TRAINING ON CHILD PHYSICAL AND SEXUAL ABUSE | — | $1,220,000 | Jul 20, 2023 | Sep 30, 2009 – Sep 19, 2013 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | RADIOPHARMACEUTICALS | VA25917D0328USAspending | $348,138 | Feb 6, 2023 | Oct 1, 2021 – Sep 30, 2022 |
| Prime | Department of Health and Human Services National Institutes of Health | TASK ORDER: FURTHER TESTING OF A MULTI-PEPTIDE KRAS VACCINE FOR PANCREATIC CANCER PREVENTION | 75N91019D00020USAspending | $493,001 | Nov 29, 2022 | Feb 21, 2020 – Aug 20, 2022 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF PREVENTION OF ENDOMETRIAL HYPERPLASIA AND ITS TRANSITION TO ENDOMETRIAL CANCER WITH SHETA2 POP 6/1/2017 - 5/31/2019 | HHSN261201500038IUSAspending | $709,326 | Apr 28, 2022 | May 19, 2017 – Jun 14, 2021 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF PREVENT EFFICACY TASK ORDER: CHEMOPREVENTION OF COLORECTAL CANCER WITH OLMESARTAN MEDOXOMIL | HHSN261201500038IUSAspending | $521,215 | Mar 30, 2022 | Sep 15, 2017 – Jun 14, 2020 |
| Prime | Department of Health and Human Services National Institutes of Health | CHEMOPREVENTION WITH AEROSOLIZED LET-7 MICRORNA IN MOUSE MODELS OF NON-SMALL CELL LUNG CANCER (ADENOCARCINOMA ANDSQUAMOUS CELL CARCINOMA) | 75N91019D00020USAspending | $849,440 | Feb 10, 2022 | Aug 28, 2019 – Aug 27, 2022 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | OPTHALMOLOGY SERVICES | — | $773,605 | Feb 10, 2022 | Jul 1, 2019 – Feb 10, 2022 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | IGF::OT::IGF NEUROSURGERY | — | $294,026 | Dec 2, 2021 | Apr 1, 2016 – Dec 2, 2021 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | RADIOPHARMACEUTICALS | VA25917D0328USAspending | $278,495 | Nov 4, 2021 | Oct 1, 2020 – Sep 30, 2021 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
5 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | MOD 2 UPDATED 4/25/2024
MOD 1 UPDATED 3/9/2023
FLOW CONTROL STRATEGIES FOR PROTECTION OF AIRCRAFT PASSENGERS AND WORKERS AGAINST SARS-COV-2 1-503851-OUHSC Parent award context Parent award agency: Department of Health and Human Services · Centers for Disease Control and Prevention Parent award NAICS: 541715 Parent award performance state: OH Parent award description: FY 2020 COVID-19 BAA TOPIC 1 - OKLAHOMA STATE View parent award on USAspending | — | $68,456 | Apr 25, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | DR. WILLIAM HILDEBRAND AT THE UNIVERSITY OF OKLAHOMA WILL PERFORM THE FOLLOWING TASKS: EXTRACTION OF THE MHC II FROM FROZEN CELL PELLETS RECEIVED FROM DR. SETTE€„¢S GROUP, IMMUNOAFFINITY PURIFY MHC II, ISOLATE THE PEPTIDES AWAY FROM MHC II AS WELL AS OTHER PROTEINS, COMPLETE LCMS ON THE PEPTIDES ELUTED FROM MHC II MOLECULES, ASSIGN SEQUENCES TO THE PEPTIDES, AND IDENTIFY B. PERTUSSIS SOURCE ANTIGENS. 30039-05-130-381 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541512 Parent award performance state: CA Parent award description: LARGE SCALE T CELL EPITOPE DISCOVERY View parent award on USAspending | — | $34,510 | Jan 10, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | DR. WILLIAM HILDEBRAND AT THE UNIVERSITY OF OKLAHOMA WILL PERFORM THE FOLLOWING TASKS: EXTRACTION OF THE MHC II FROM FROZEN CELL PELLETS RECEIVED FROM DR. SETTE€„¢S GROUP, IMMUNOAFFINITY PURIFY MHC II, ISOLATE THE PEPTIDES AWAY FROM MHC II AS WELL AS OTHER PROTEINS, COMPLETE LCMS ON THE PEPTIDES ELUTED FROM MHC II MOLECULES, ASSIGN SEQUENCES TO THE PEPTIDES, AND IDENTIFY B. PERTUSSIS SOURCE ANTIGENS. 30039-04-130-381 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541512 Parent award performance state: CA Parent award description: LARGE SCALE T CELL EPITOPE DISCOVERY View parent award on USAspending | — | $45,649 | Dec 5, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | PAYMENTS IN THE AMOUNT OF $120,000 PER PHASE 1 OF EACH COHORT (1 COHORT CONSISTS OF MINIMUM OF 15 NURSING HOMES, PHASE 1 CONSISTS OF THE 16-WEEK TELEECHO TRAINING PROGRAM) RECRUITED AND LAUNCHED. THE SUB-CONTRACTOR WILL RECEIVE $120,000 UPON THE EXECUTION OF THE SUB-CONTRACT TO SUPPORT THE LAUNCH AND REPORTING FOR THE FIRST COHORT, AND WILL HAVE 21 DAYS TO LAUNCH AFTER RECEIVING THE INITIAL PAYMENT. FOR EACH SUBSEQUENT COHORT LAUNCHED, THE PARTNER WILL RECEIVE A PAYMENT OF $120,000 (TO BE INVOICED AFTER THE FIRST TELEECHO SESSION IS HELD).
SHOULD THE NH CAN PERIOD OF PERFORMANCE BE EXTENDED BY THE ECHO INSTITUTE, TRAINING CENTERS WILL BE ASKED TO EXTEND THEIR WORK WITH NURSING HOMES BEYOND THE INITIAL 16-WEEK TRAINING TO AN ADDITIONAL 19- WEEK COMMUNITY OF ONGOING LEARNING (CONTINUATION PHASE). PLEASE SEE THE PAYMENT STRUCTURE BELOW. 3JK70 Parent award context Parent award agency: Department of Health and Human Services · Agency for Healthcare Research and Quality Parent award NAICS: 541720 Parent award performance state: NM Parent award description: THE NATIONAL NURSING HOME COVID ACTION NETWORK View parent award on USAspending | — | $320,000 | Feb 4, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | DR. WILLIAM HILDEBRAND AT THE UNIVERSITY OF OKLAHOMA WILL PERFORM THE FOLLOWING TASKS: EXTRACTION OF THE MHC II
FROM FROZEN CELL PELLETS RECEIVED FROM DR. SETTE€„¢S GROUP, IMMUNOAFFINITY PURIFY MHC II, ISOLATE THE PEPTIDES AWAY
FROM MHC II AS WELL AS OTHER PROTEINS, COMPLETE LCMS ON THE PEPTIDES ELUTED FROM MHC II MOLECULES, ASSIGN
SEQUENCES TO THE PEPTIDES, AND IDENTIFY B. PERTUSSIS SOURCE ANTIGENS. 30039-03-130-381 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541512 Parent award performance state: CA Parent award description: LARGE SCALE T CELL EPITOPE DISCOVERY View parent award on USAspending | — | $74,436 | Nov 29, 2021 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Veterans AffairsGov-sourced
- Department of Health and Human ServicesGov-sourced
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.